In a study of 270 melanoma patients treated with high-dose bolus interleukin-2 reported by the Cytokine Working Group in 1999 (1), there were only 12 patients who were progression-free 3 to 9 years after beginning therapy, and none of those 12 patients had relapsed during that time period, with a median follow-up of 62 months and a maximum follow-up of 108 months. Here, IL2 is linked to melanoma.